XML 53 R29.htm IDEA: XBRL DOCUMENT
v3.20.2

SEGMENT INFORMATION (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Segment Reporting [Abstract] |
Information About Reportable Segments and Reconciliation of Segment Net Sales to Consolidated Net Sales and Segment Pre-Tax Income to Consolidated Pre-Tax Income | The table below presents information about Edwards Lifesciences' reportable segments (in millions):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Segment Net Sales |  |  |  |  |  |  |  |  |  |  |
United States | $ | 662.0 |  |  | $ | 647.8 |  |  | $ | 1,845.6 |  |  | $ | 1,835.5 |
Europe | 241.5 |  |  | 219.8 |  |  | 695.9 |  |  | 684.3 |
Japan | 109.9 |  |  | 110.0 |  |  | 325.0 |  |  | 322.9 |
Rest of World | 115.2 |  |  | 112.0 |  |  | 323.4 |  |  | 316.5 |
Total segment net sales | $ | 1,128.6 |  |  | $ | 1,089.6 |  |  | $ | 3,189.9 |  |  | $ | 3,159.2 |
Segment Operating Income |  |  |  |  |  |  |  |  |  |  |
United States | $ | 453.8 |  |  | $ | 447.4 |  |  | $ | 1,264.0 |  |  | $ | 1,258.3 |
Europe | 124.2 |  |  | 111.5 |  |  | 356.2 |  |  | 353.2 |
Japan | 69.2 |  |  | 70.7 |  |  | 209.9 |  |  | 202.8 |
Rest of World | 35.6 |  |  | 36.7 |  |  | 105.2 |  |  | 99.8 |
Total segment operating income | $ | 682.8 |  |  | $ | 666.3 |  |  | $ | 1,935.3 |  |  | $ | 1,914.1 |
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Net Sales Reconciliation |  |  |  |  |  |  |  |  |  |  |
Segment net sales | $ | 1,128.6 |  |  | $ | 1,089.6 |  |  | $ | 3,189.9 |  |  | $ | 3,159.2 |
Foreign currency | 12.3 |  |  | 4.4 |  |  | 4.7 |  |  | 14.7 |
Consolidated net sales | $ | 1,140.9 |  |  | $ | 1,094.0 |  |  | $ | 3,194.6 |  |  | $ | 3,173.9 |
Pre-tax Income Reconciliation |  |  |  |  |  |  |  |  |  |  |
Segment operating income | $ | 682.8 |  |  | $ | 666.3 |  |  | $ | 1,935.3 |  |  | $ | 1,914.1 |
Unallocated amounts: |  |  |  |  |  |  |  |  |  |  |
Corporate items | (331.9 | ) |  | (384.2 | ) |  | (1,005.6 | ) |  | (1,073.1 | )
Special charge (Note 4) | — |  |  | — |  |  | — |  |  | (24.0 | )
Intellectual property litigation expenses | (8.4 | ) |  | (7.9 | ) |  | (400.8 | ) |  | (19.5 | )
Change in fair value of contingent consideration liabilities, net | 9.0 |  |  | 2.3 |  |  | (8.4 | ) |  | (12.4 | )
Foreign currency | 6.3 |  |  | 17.8 |  |  | 25.7 |  |  | 50.9 |
Consolidated operating income | 357.8 |  |  | 294.3 |  |  | 546.2 |  |  | 836.0 |
Non-operating income | 6.5 |  |  | 7.4 |  |  | 14.4 |  |  | 15.0 |
Consolidated pre-tax income | $ | 364.3 |  |  | $ | 301.7 |  |  | $ | 560.6 |  |  | $ | 851.0 |
Enterprise-Wide Information | nterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
| (in millions)
Net Sales by Geographic Area |  |  |  |  |  |  |  |  |  |  |
United States | $ | 662.0 |  |  | $ | 647.8 |  |  | $ | 1,845.6 |  |  | $ | 1,835.5 |
Europe | 253.8 |  |  | 222.6 |  |  | 707.8 |  |  | 699.0 |
Japan | 113.9 |  |  | 112.9 |  |  | 330.7 |  |  | 324.4 |
Rest of World | 111.2 |  |  | 110.7 |  |  | 310.5 |  |  | 315.0 |
| $ | 1,140.9 |  |  | $ | 1,094.0 |  |  | $ | 3,194.6 |  |  | $ | 3,173.9 |
Net Sales by Major Product Group |  |  |  |  |  |  |  |  |  |  |
Transcatheter Aortic Valve Replacement | $ | 744.6 |  |  | $ | 700.0 |  |  | $ | 2,081.1 |  |  | $ | 1,975.4 |
Transcatheter Mitral and Tricuspid Therapies | 12.1 |  |  | 9.7 |  |  | 28.7 |  |  | 21.0 |
Surgical Structural Heart | 203.3 |  |  | 204.1 |  |  | 557.6 |  |  | 636.6 |
Critical Care | 180.9 |  |  | 180.2 |  |  | 527.2 |  |  | 540.9 |
| $ | 1,140.9 |  |  | $ | 1,094.0 |  |  | $ | 3,194.6 |  |  | $ | 3,173.9 |
| September 30, 2020 |  | December 31, 2019
| (in millions)
Long-lived Tangible Assets by Geographic Area |  |  |  |  |
United States | $ | 1,031.9 |  |  | $ | 849.1 |
Europe | 159.1 |  |  | 101.5 |
Japan | 18.6 |  |  | 21.7 |
Rest of World | 293.3 |  |  | 269.4 |
| $ | 1,502.9 |  |  | $ | 1,241.7 |

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration